INTRODUCTION {#S5}
============

Gestational diabetes mellitus (GDM) is common and complicates approximately 5--10% of all pregnancies ([@R1]). Substantial rates of maternal and neonatal complications are associated with GDM. However, in addition to short-term neonatal morbidities, multiple studies demonstrate that offspring of mothers with GDM have an increased risk to develop several chronic diseases including hypertension, obesity, type 2 diabetes (T2DM) and the metabolic syndrome ([@R2]--[@R5]). Despite the evidence that exists linking prenatal exposure to GDM to several diseases later in life, the mechanism for disease pathogenesis is currently unknown.

Individuals with diabetes mellitus (DM) are at a high risk to develop micro- and macrovascular diseases, demonstrating that a diabetic environment promotes vascular injury ([@R6]). Endothelial dysfunction precedes the development of many vascular diseases ([@R7]). The repair of damaged endothelium requires intact function of progenitor cells that reside in vessel walls and that circulate in the peripheral blood ([@R8],[@R9]). Studies in adults and adolescents with DM show that reduced numbers and altered function of circulating progenitors are associated with endothelial dysfunction ([@R10],[@R11]). Given these observations, we hypothesize that fetal exposure to a diabetic environment accelerates the onset of endothelial dysfunction by altering endothelial progenitor quantity and function.

Studies by our lab and others have characterized highly proliferative circulating endothelial progenitor cells referred to as endothelial colony forming cells (ECFCs) ([@R8],[@R9],[@R12],[@R13]). Previously, we demonstrated that ECFCs from the cord blood of infants born to women with pregestational DM have reduced colony formation, premature senescence, decreased proliferation, and decreased vessel forming ability compared to control cord blood ECFCs ([@R13]). Because ECFCs from neonates born to women with GDM are also exposed to the diabetic milieu *in utero*, we hypothesized that cord blood ECFCs from GDM pregnancies would also exhibit altered function.

RESULTS {#S6}
=======

ECFCs from GDM pregnancies exhibit increased proliferation and reduced tube formation {#S7}
-------------------------------------------------------------------------------------

The ability of a single cell to form a visible colony in vitro is a key defining characteristic of progenitor cells. Therefore, ECFCs from the cord blood of control and GDM pregnancies were plated in limiting dilution assays to validate progenitor function via colony-forming ability. In contrast to our previous data with ECFCs from pregnancies complicated by pregestational DM ([@R13]), GDM and control ECFCs had similar colony formation frequencies, both from original cord blood samples ([Figure 1a](#F1){ref-type="fig"}) and from established cell lines ([Figure 1b](#F1){ref-type="fig"}). To determine whether intrauterine exposure to GDM altered ECFC function, *in vitro* assays were performed to assess senescence by staining for senescence-associated β-galactosidase (SA-β-gal) ([@R14]), proliferation using 3H thymidine incorporation assays, and network-forming ability in Matrigel studies. Baseline levels of senescence were negligible in both GDM and control ECFCs (data not shown). However, proliferation of GDM exposed ECFCs was significantly increased compared to controls ([Figure 1c](#F1){ref-type="fig"}).

To further examine ECFCs from GDM pregnancies for evidence of dysfunction, cells were plated on Matrigel extracellular matrix to assess their ability to form closed network structures *in vitro*. Compared to control ECFCs, GDM ECFCs made \~30% fewer closed networks ([Figure 1d](#F1){ref-type="fig"}). Taken together, these findings are intriguing given that ECFCs from GDM pregnancies were hyperproliferative, yet had poor network formation in Matrigel studies. We questioned whether the enhanced proliferation observed in ECFCs from GDM pregnancies predisposes the cells to premature senescence.

Aging of cells to induce senescence can be modeled *in vitro* via serial replating. Therefore, we next asked whether higher passage GDM ECFCs retained their hyperproliferative state and/or became senescent. Serial replating of ECFCs from GDM pregnancies showed that these cells had a reduced proliferative response both to baseline and growth factor stimulated conditions. As is shown in [Figure 2a](#F2){ref-type="fig"}, higher passage GDM ECFCs were no longer hyperproliferative and trended toward decreased proliferation. SA-β-gal assays confirmed that serial replating of GDM ECFCs enhanced senescence compared to controls ([Figure 2b](#F2){ref-type="fig"}). The increase in proliferation of early passage GDM ECFCs may lead to subsequent premature senescence and reduced proliferation.

ECFCs from GDM pregnancies are resistant to hyperglycemia-induced senescence {#S8}
----------------------------------------------------------------------------

Previously, we demonstrated that control ECFCs exhibit enhanced senescence when exposed to hyperglycemia *in vitro* ([@R13]). It is possible that ECFCs from GDM pregnancies also undergo senescence in response to hyperglycemia. Alternatively, since ECFCs from GDM pregnancies were exposed to hyperglycemia *in utero* and have no increase in baseline senescence, GDM ECFCs may have adapted to the deleterious effects of hyperglycemia. To determine whether ECFCs from GDM pregnancies undergo senescence following treatment with elevated glucose concentrations, control and GDM ECFCs were cultured in euglycemic (5 mmol/l glucose) and hyperglycemic conditions (10 or 15 mmol/l glucose). As shown in [Figure 3a](#F3){ref-type="fig"} and similar to previous studies ([@R13]), treating control ECFCs with either 10 or 15 mmol/l glucose induced a greater frequency of senescent cells. However, exposing ECFCs from GDM pregnancies to hyperglycemia did not increase senescence, resulting in significantly lower senescence compared to control cells. In addition, culturing ECFCs in elevated glucose concentrations did not increase numbers of apoptotic or necrotic cells in control or GDM ECFCs (data not shown). These data indicate that GDM ECFCs are resistant to hyperglycemia-induced senescence and suggest that adaptive changes have occurred that protect from hyperglycemic stress.

Previous studies demonstrate that p38MAPK is required for hyperglycemia-induced senescence in adult endothelial progenitor cells ([@R15],[@R16]). However, the role of p38MAPK in promoting senescence of neonatal ECFCs after hyperglycemic exposure is unknown. Therefore, our initial studies evaluated whether control ECFCs treated with either 10 or 15 mmol/l glucose increased p38MAPK activation. Hyperglycemic treatment of control ECFCs stimulated a dose-dependent increase in phosphorylated or active p38MAPK ([Figures 3b--3c](#F3){ref-type="fig"}). To determine whether ECFC senescence was dependent on p38MAPK activation, control ECFCs were cultured with or without a p38MAPK inhibitor, SB203580, in euglycemic and hyperglycemic conditions. Inhibition of p38MAPK prevented hyperglycemia-induced senescence in control ECFCs ([Figure 3d](#F3){ref-type="fig"}), supporting an integral role for this stress-activated pathway in regulating senescence of ECFCs.

Given that p38MAPK is required for hyperglycemia-induced senescence together with the observation that GDM ECFCs do not undergo senescence after hyperglycemic treatment, we speculated that activation of p38MAPK was impaired in ECFCs from GDM pregnancies. As is shown in [Figure 3b](#F3){ref-type="fig"} and quantified in [Figure 3c](#F3){ref-type="fig"}, high glucose treatment of ECFCs from GDM pregnancies did not increase p38MAPK phosphorylation. These results are consistent with the idea that p38MAPK is required for hyperglycemia to induce senescence in ECFCs and indicate that resistance of GDM ECFCs to hyperglycemia-induced senescence may be due to aberrant regulation of p38MAPK activation.

To confirm a role for the p38MAPK pathway in regulating senescence of ECFCs, mutant cDNAs of mitogen activated protein kinase kinase 6 (MKK6) were stably expressed in ECFCs using lentiviral transduction methods ([@R17]). MKK6 was chosen because it directly and specifically activates p38MAPK by phosphorylating residues in the activation loop ([@R18]). Initially, a control ECFC cell line was transduced with lentiviral vectors encoding either an empty vector, a constitutively active MKK6, or an inactive MKK6 construct. Western blotting confirmed MKK6 overexpression in cells transduced with lentiviruses encoding the mutant MKK6 cDNAs and verified increased phosphorylation of p38MAPK in cells overexpressing constitutively active MKK6 ([Figure 4a](#F4){ref-type="fig"}). For subsequent studies, control and GDM ECFC cell lines expressing either the constitutively active or inactive MKK6 constructs were evaluated for senescence under standard culture conditions. Both control and GDM ECFCs expressing constitutively active MKK6 had increased senescent cells compared to ECFCs expressing inactive MKK6 ([Figure 4b](#F4){ref-type="fig"}). Previous studies demonstrated that the molecule downstream of p38MAPK required for promoting a senescent cellular fate is p16^INK4A^, a cyclin dependent kinase inhibitor ([@R19]). Therefore, we next examined transduced cells for p16^INK4A^ expression by RTPCR and Western blotting. In control and GDM ECFCs with increased p38MAPK activity, p16^INK4A^ expression was significantly elevated at the RNA and protein levels compared to controls expressing the inactive MKK6 mutant ([Figures 4c--d](#F4){ref-type="fig"}). Collectively, these data support an important role for the p38MAPK pathway in regulating senescence of ECFCs as well as support aberrant regulation of p38MAPK in ECFCs from GDM pregnancies.

DISCUSSION {#S9}
==========

Infants exposed to either GDM or pregestational DM *in utero* are at increased risk to develop several chronic diseases, and in some cases, with onset of symptomatology during childhood ([@R2]--[@R5]). Increases in systolic blood pressure and adiposity can be detected as early as 3 years of age in children born to women with GDM ([@R2]). Furthermore, offspring of pregnancies complicated by either GDM or pregestational DM exhibit an enhanced risk for childhood onset of elevated blood pressure, overt hypertension, T2DM, and obesity ([@R3],[@R5]). These complications have immediate health consequences for individual children. Moreover, each of these morbidities constitutes a significant risk factor for eventual cardiovascular mortality. Thus, it is critical to identify underlying mechanisms involved in disease pathogenesis so that preventative measures can be instituted prospectively in children of mothers with DM.

Fetal exposure to an adverse intrauterine environment likely results in alterations in long-lived stem and progenitor cells, especially given the early acquisition of chronic diseases in offspring typically found in older adults. The model of stem and/or progenitor cell damage and subsequent dysfunction as a mechanism involved in vascular disease progression has been described previously ([@R20],[@R21]). However, minimal data are reported to support this concept in the developmental origins of vascular disease. ECFCs, an important progenitor population critical for vascular homeostasis, circulate in adult peripheral blood but are highly enriched in the endothelium of vessel walls and in umbilical cord blood ([@R8]). Circulating levels of ECFCs are altered in patients with coronary artery disease and diabetic retinopathy ([@R12],[@R22],[@R23]). Healthy adolescents and young adults with T1DM have altered circulating levels of ECFCs and evidence of endothelial dysfunction ([@R11]). Importantly, pulmonary artery ECFCs from patients with pulmonary artery hypertension exhibit increased proliferation ([@R24]). Based on these previous studies correlating ECFC levels and function to vascular disease, ECFCs represent a novel and accessible progenitor population to study the effects of an adverse intrauterine environment.

Previously, to test this notion, we examined ECFCs harvested from pregnancies complicated by pregestational DM for functional impairments. Pregestational DM ECFCs had decreased colony formation, reduced proliferative capacity, increased basal senescence, and profound deficiencies in vasculogenesis ([@R13]). In the current studies, we examined whether ECFCs from GDM pregnancies would be less dysfunctional since GDM is often associated with milder diabetic symptoms for a shorter duration as compared to pregestational DM ([@R25]). While several progenitor phenotypes examined support this concept (i.e. normal colony formation, normal baseline senescence, and modest reduction in tube forming ability), an unexpected finding was baseline hyperproliferation of GDM ECFCs. We speculate that this observation may reflect an adaptive response of ECFCs following intrauterine exposure to a GDM environment. However, increased proliferation was only transient. Passaging of GDM ECFCs led to decreased proliferative responses and premature senescence, which are remarkably similar to phenotypes observed in ECFCs from pregnancies complicated by type 1 and type 2 DM. It is possible that ECFCs exposed to pregestational DM may also exhibit a compensatory period of hyperproliferation. Due to the greater severity and/or longer exposure to the intrauterine DM environment, neonatal ECFCs harvested from pregestational DM pregnancies may have already progressed toward reduced proliferation and enhanced senescence. Future studies in animal models could be used to test this hypothesis, given the lack of feasibility in evaluating fetal ECFCs from human subjects.

Another adaptation identified in GDM ECFCs was resistance to hyperglycemia-induced senescence. The tolerance to hyperglycemia likely occurs through a signaling alteration involving p38MAPK, which is activated and required for senescence of control ECFCs. GDM ECFCs treated with hyperglycemia did not activate p38MAPK, allowing the cells to resist senescence and to continue proliferating in the presence of elevated glucose concentrations. GDM ECFCs were capable of phosphorylating p38MAPK and undergoing senescence when an upstream activating molecule, MKK6, was expressed. Together these data support dysregulation of p38MAPK activity in ECFCs from GDM pregnancies, rather than an intrinsic defect in the ability of the ECFCs to undergo senescence. Though further studies are needed to elucidate the underlying mechanism responsible for aberrant p38MAPK regulation, our data identified novel cellular and biochemical adaptations in a primary neonatal progenitor population after *in vivo* GDM exposure. Our findings and approach have advantages compared to previous studies that examined biochemical and molecular alterations of endothelial cells treated with hyperglycemia *in vitro* ([@R16],[@R26],[@R27]) since the neonatal impact of GDM exposure is challenging to model *in vitro* or to replicate in animal models. This is due to the complexity of GDM, which involves maternal insulin resistance, beta-cell dysfunction, hyperlipidemia, and inflammation resulting in fetal hyperglycemia, hyperinsulinemia, and presumably additional metabolic consequences yet to be identified ([@R28]). Therefore, studying ECFCs after *in vivo* GDM exposure enhances physiologic relevance and provides unique insight into the long-term effects of the overall diabetic milieu on a neonatal progenitor cell population.

METHODS {#S10}
=======

Cord blood sample collection {#S11}
----------------------------

Umbilical cord blood samples were collected from healthy, control pregnancies and pregnancies complicated by GDM after informed consent was obtained from the mothers. All pregnancies were singleton gestations. GDM was defined according to the American College of Obstetrics and Gynecology guidelines ([@R29]). All control subjects had a normal 50-gram oral glucose screen. Women with preeclampsia or hypertension were excluded as were women with other illnesses known to affect glucose metabolism or taking medications known to affect glucose metabolism. In addition, infants with known chromosomal abnormalities were excluded. The Institutional Review Board at the Indiana University School of Medicine approved this protocol. Pertinent health information is included for women ([Table 1](#T1){ref-type="table"}) and infants ([Table 2](#T2){ref-type="table"}) enrolled in the study.

ECFC culture and isolation {#S12}
--------------------------

ECFCs were isolated from cord blood samples by the Indiana University Simon Cancer Center's Angiogenesis, Endothelial and Pro-Angiogenic Cell Core (AEPCC) as previously described ([@R13],[@R30]). For routine culture of ECFCs, cells were grown in EGM2 (Lonza, Walkersville, MD) containing 10% FCS (Thermo Scientific Hyclone, Logan, UT). EGM2 is euglycemic (5 mmol/l). For hyperglycemia experiments, ECFCs were cultured in EGM2 supplemented with glucose to achieve concentrations of 10 or 15 mmol/l. Early passage ECFCs (less than passage 5) were used in all experiments, except where late passage ECFCs are indicated (passage 7).

Colony Formation Assays {#S13}
-----------------------

Each assay was performed in triplicate, plating 200 cells per well as described ([@R13]). Average counts of total colonies from 5--7 cell lines from control and GDM groups are shown.

^3^H-Thymidine Incorporation Assay {#S14}
----------------------------------

Studies were performed as previously described ([@R13]). ECFCs were incubated in EBM2 containing 5% FCS overnight and then plated in triplicate at 50,000 cells per well of a 6-well plate in EBM2 with 1% FCS for 16 hours. ECFCs were then cultured in serum-free EBM2 for 8 hours to induce quiescence. Proliferation was induced by addition of 2% FCS for 16 hours. Cells were pulsed with 1 µCi ^3^H-thymidine (Perkin-Elmer, Boston, MA) for 5 hours, washed, and then lysed in 0.1M NaOH. Incorporated ^3^H-thymidine was quantified on a liquid scintillation counter for triplicate wells. Average counts in 4 independent experiments were normalized to values obtained from control cells.

Senescence-Associated Beta-Galactosidase (SA-β-gal) Staining {#S15}
------------------------------------------------------------

ECFCs were cultured in EGM2 containing the indicated concentration of glucose for 7 days. Staining was performed as described ([@R13],[@R14]). Triplicate wells were plated for all conditions. At least 100 total cells per well were scored, and the average percentage of SA-β-gal positive cells was determined per sample. Senescence was quantified for *in vitro* aged cells in 3 independent experiments and following hyperglycemia in 4 independent experiments.

Matrigel Assay {#S16}
--------------

Tube forming ability on Matrigel was conducted as described ([@R13]). Briefly, 96-well plates were coated with 50 µl Matrigel (Becton Dickenson, Franklin Lakes, NJ). ECFCs were plated on in triplicate at a density of 5000 cells per well in EGM2. After incubating at 37°C for 16 hours, phase contrast images were taken using a Spot camera (Spot Imaging Solutions, Sterling Heights, MI) on an Axiovert 35 microscope (Zeiss, Thornwood, NY). The number of closed networks per well was scored. Triplicate measurements were averaged for each of 4 cell lines per group.

Western blotting {#S17}
----------------

Cells were lysed in RIPA buffer containing Complete Protease Inhibitor Cocktail (Roche Applied Science, Indianapolis, IN). Equal protein amounts were separated by gel electrophoresis on precast gels (Life Technologies, Grand Island, NY). Protein was transferred to nitrocellulose, and immunoblotted with antibodies to either phosphorylated-p38MAPK, total p38MAPK, MKK6, (Cell Signaling Technology, Beverly, MA), p16^INK4a^ (ab81278, Abcam, Cambridge, MA), or β-actin (Sigma-Aldrich Inc., St. Louis, MO). Secondary antibodies conjugated to HRP were from Biorad (Hercules, CA). Blots were developed with Pierce Supersignal West Pico (ThermoFisher, Hanover Park, IL), exposed to film, scanned and compiled in Photoshop CS5.1 (Adobe, San Jose, CA). Band intensity was quantified using ImageJ (NIH, Bethesda, MD). Graphs of semi-quantitative data were generated on 3--6 cell lines per group.

Generation of lentivirus encoding recombinant MKK6 cDNA constructs {#S18}
------------------------------------------------------------------

Plasmids containing cDNA for a constitutively active mitogen activated protein kinase kinase 6 (MKK6 Glu; Addgene plasmid 13518) or kinase inactive MKK6 (K82A; Addgene plasmid 13519) were a generous gift from Dr. Roger Davis ([@R18]). The cDNAs were subcloned into the lentiviral vector (pUC2CL6IPwo), which was obtained from Dr. Helmut Hanenberg ([@R17]). The lentiviral vector contains a puromycin resistance gene to enable selection of transduced cells. Lentivirus was produced by co-transfection of HEK-293T cells with a lentiviral vector, packaging plasmid pCD/NL-BH, and VSV-G envelope plasmid using Fugene 6 (Roche, Indianapolis, IN). Lentivirus-containing supernatants were then collected, filtered through an 0.45µM asymmetric polyethersulfone filter unit (Thermo Scientific, Waltham, MA), and stored at −80°C.

Lentiviral transduction of ECFCs {#S19}
--------------------------------

ECFCs were plated at 25,000 cells per well in a 6-well tissue culture dish the day prior to transduction. Lentiviral vector supernatant was added to each well at a dilution of 1:5--1:10, in a final volume of 1mL of EGM2 + 10% FCS containing 21µM (8µg/mL) Polybrene (Sigma, St. Louis, MO), and incubated overnight. Media was changed, and plates were then incubated for 48h. Transduced cells were selected in media containing 1.8 µM (1µg/mL) puromycin (Life Technologies, Grand Island, NY) for 2 days or until no live cells remained in the selection control plate. Protein lysates were obtained as described, and MKK6 expression and phosphorylated p38MAPK levels were confirmed for each transduction by western blotting.

Real-time RT-PCR {#S20}
----------------

ECFCs were lysed in Qiazol (Qiagen, Valencia, CA), and RNA was obtained using manufacturer's instructions. RNA was reverse transcribed using a Transcriptor Universal cDNA Master Kit (Roche). RTPCR was performed on a Lightcycler 480 (Roche). For detection of p16^INK4a^, a Universal Probe Master mix was used with Probe \#34 from the Roche Universal Probe Library, and p16^INK4a^ primers (5'-GTGGACCTGGCTGAGGAG-3' and 5'-CTTTCAATCGGGGATGTCTG-3'). HPRT was used to normalize p16^INK4a^ values using the 2^−ΔΔCt^ method. Detection of HPRT was performed using Lightcycler 480 SYBR Green I Master Mix (Roche) and HPRT primers: 5'-CCTTGGTCAGGCAGTATAATCCA-3'; 5'-GGTCCTTTTCACCAGCAAGCT-3').

Statistical analysis {#S21}
--------------------

Data illustrated are mean +/− SEM. Two-way ANOVAs, followed by Sidak's multiple comparisons or Kruskal-Wallis one-way ANOVAs were performed on comparisons of more than two groups, as indicated in the figure legends. Unpaired t-tests were conducted when only two groups were compared and data were normally distributed. Prism 6 (GraphPad Software, La Jolla, CA) was used for all statistical analyses, and significance was noted when p\<0.05.
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![GDM ECFCs exhibit increased proliferation and impaired tube forming ability\
(**a**) Frequency of ECFC colonies per 10^8^ cord blood mononuclear cells (MNC). Approximately 2 × 10^8^ MNC were plated on collagen-coated plates. Colonies were counted between days 10--14. Frequency of ECFCs was calculated by normalizing to cell number plated for each sample, n=5 for control and n=7 for GDM samples. (**b**) Frequency of ECFC colonies in limiting dilution assays. Colonies were scored by visual inspection after 7 days in culture, n=6 per group. (**c**) ^3^H-Thymidine incorporation assay to assess proliferation. Relative proliferation was calculated by dividing the scintillation count for individual culture conditions by the baseline value for control ECFCs then multiplying by 100. Results are from 7 independent experiments using 5--6 different cell lines per group. White bars indicate control ECFCs, and black bars indicated GDM ECFCs. \*p\<0.05 by Wilcoxan signed rank test. (**d**) Network formation in Matrigel. ECFCs were plated in Matrigel for 16 hours. Images were obtained and total closed networks per well were quantified, n=4 per group, \*p\<0.05 compared to control by unpaired t test.](nihms548715f1){#F1}

![Serial passage of ECFCs from GDM pregnancies decreased proliferation and increased senescence\
(**a**) ^3^H-Thymidine incorporation assay to assess proliferation as described previously ([@R13]). Relative proliferation was calculated by dividing the scintillation count for individual culture conditions by the baseline value for control ECFCs then multiplying by 100, n=4. White bars indicate control ECFCs, and black bars indicated GDM ECFCs. Serial passaged GDM ECFCs were no longer more proliferative than similarly passaged control ECFCs (not significant by unpaired t test). (**b**) Senescence after serial passage. Frequency of SA-β-gal positive cells was measured in passage 7 ECFCs, n= 3, \*p\<0.05 by unpaired t test.](nihms548715f2){#F2}

![Hyperglycemic treatment of GDM ECFCs did not induce senescence or activate p38MAPK\
(**a**) Hyperglycemia-induced senescence. ECFCs were plated in EGM2 containing the indicated glucose concentration for 7 days. The percentage of SA-β-gal positive cells was calculated in 4 independent experiments. White bars indicate control ECFCs, and black bars indicated GDM ECFCs. Two-way ANOVA determined a significant increase in senescence by hyperglycemia, and with significantly less senescence in GDM ECFCs. \*p\<0.05 by Sidak's multiple comparison. (**b**) Hyperglycemia induced p38MAPK phosphorylation in ECFCs. Western blotting was performed on lysates from control ECFCs treated with indicated glucose concentrations to detect phospho-p38MAPK and total p38MAPK. β-actin was used as a loading control. (**c**) Quantitation of band intensity from Western blots in panel (b) in 6 independent experiments. Bands were quantified in ImageJ. Phospho-p38MAPK (P-p38MAPK) levels were normalized to total p38MAPK. A significant increase in p38MAPK phosphorylation with higher glucose concentration was found by 2-way ANOVA. Decreased phospho-p38MAPK was found in GDM ECFCs as indicated (\*p\<0.05) by Sidak's multiple comparisons. (d) Effect of p38MAPK inhibition on senescence. Control ECFCs were cultured in 5, 10, or 15 mmol/l glucose with or without 1 µM of the p38MAPK inhibitor, SB203580. White bars indicate control ECFCs, and black bars indicated GDM ECFCs. After 7 days, the percentage of SA-β-gal positive cells was quantified. Results are from 4 independent experiments. SB203580 signficantly decreased senescence, with \*p\<0.05 as indicated (two-way ANOVA followed by Sidak's multiple comparisons).](nihms548715f3){#F3}

![Activation of p38MAPK in ECFCs induces senescence and p16 expression\
(a) Overexpression of active MKK6 by lentiviral transduction in control ECFCs increases phospho-p38MAPK. Control ECFCs were also transduced by lentivirus expressing empty vector or kinase inactive MKK6. Western blotting of lysates confirmed increased phospho-p38MAPK by active MKK6, but not empty vector or inactive MKK6. Blot is representative of 3 independent experiments. (b) Effect of p38MAPK activation by active MKK6 on senescence in control and GDM ECFCs. Following transduction with either active or inactive MKK6, the percentage of SA-β--gal positive control and GDM ECFCs was assessed. White bars indicate control ECFCs, and black bars indicated GDM ECFCs. Expression of active MKK6 induced significantly increased senescence in both control and GDM ECFCs, by two-way ANOVA (\*p\<0.05). No differences between control and GDM were found by Sidak's multiple comparisons. Results shown are from 3 independent experiments. (c) p16^INK4a^ expression is increased following expression of active MKK6, but not inactive MKK6. RNA was isolated from control and GDM ECFCs overexpressing active or inactive MKK6. Relative mRNA levels of p16^INK4a^ were quantified by real-time RTPCR, normalizing to HPRT expression. White bars indicate control ECFCs, and black bars indicate GDM ECFCs. Two-way ANOVA identified a significant increase in p16^INK4a^ mRNA in ECFCs overexpressing active MKK6 compared to ECFCs expressing inactive MKK6 (\*p\<0.05). No significant difference was found between control and GDM. Results represent 3 different cell lines from both control and GDM groups. (d) Western blotting confirmed increased expression of p16^INK4a^ with active MKK6 and p38MAPK activation (P-p38MAPK). Total p38MAPK is shown as a loading control. Blots are representative of 3 independent experiments.](nihms548715f4){#F4}

###### 

Clinical data for maternal subjects

  -----------------------------------------------------------------------------------
              Maternal age\   Medications         Maternal prepregnancy BMI   HbA1c
              (years)                                                         
  ----------- --------------- ------------------- --------------------------- -------
  Control 1   26              Penicillin          48                          ND

  Control 2   38              None                28                          ND

  Control 3   26              None                44                          ND

  Control 4   37              None                37                          ND

  Control 5   42              None                35                          ND

  Control 6   24              Zoloft              19                          ND

  GDM 1       32              None                31                          5.8

  GDM 2       28              Insulin             27                          6.4

  GDM 3       24              None                44                          6.2

  GDM 4       25              None                37                          ND

  GDM 5       41              Penicillin          34                          5.9

  GDM 6       33              Glyburide, Zoloft   39                          5.6

  GDM 7       37              None                20                          5.7
  -----------------------------------------------------------------------------------

ND=not done

###### 

Clinical data for infant subjects

  --------------------------------------------------------------------------------------------------------------------------------------------------
              Sex      Gestational age\   Infant weight\   Infant weight\                               Infant weight/length\
                       (weeks complete)   (kg)             percentile[\*](#TFN2){ref-type="table-fn"}   percentile[\*](#TFN2){ref-type="table-fn"}
  ----------- -------- ------------------ ---------------- -------------------------------------------- --------------------------------------------
  Control 1   Male     38                 3.10             10--25%                                      25%

  Control 2   Female   40                 3.38             25--50%                                      10--25%

  Control 3   Male     41                 3.98             75--90%                                      25--50%

  Control 4   Male     39                 3.70             50--75%                                      10--25%

  Control 5   Female   38                 2.91             10--25%                                      5--10%

  Control 6   Female   40                 3.45             50--75%                                      90--95%

  GDM 1       Male     38                 4.06             75--90%                                      50%

  GDM 2       Female   39                 4.18             95--97%                                      95--97%

  GDM 3       Female   39                 3.76             75--90%                                      75--90%

  GDM 4       Male     37                 3.09             10--25%                                      5%

  GDM 5       Female   39                 3.21             25--50%                                      25%

  GDM 6       Male     39                 3.61             50--75%                                      50--75%

  GDM 7       Female   38                 3.47             50--75%                                      25--50%
  --------------------------------------------------------------------------------------------------------------------------------------------------

Percentiles obtained from CDC 2000 Clinical Growth Charts (<http://www.cdc.gov/growthcharts/clinical_charts.htm>).
